Yes, methotrexate and tofacitinib can be combined, and this combination is explicitly recommended and supported by high-quality evidence.
The combination of tofacitinib with methotrexate is a standard, guideline-endorsed treatment strategy for rheumatoid arthritis, particularly in patients with inadequate response to methotrexate alone. 1, 2
Evidence Supporting Combination Therapy
Guideline Recommendations
The 2020 EULAR guidelines explicitly position JAK inhibitors (including tofacitinib) as appropriate add-on therapy when patients have poor prognostic factors and fail to achieve treatment targets with methotrexate alone 2. The 2021 consensus statement on JAK inhibitors confirms that combination therapy with methotrexate is both effective and appropriate 1.
Clinical Efficacy Data
The combination demonstrates superior outcomes compared to either agent alone:
- Head-to-head trial data: Tofacitinib 5 mg twice daily plus methotrexate was non-inferior to adalimumab plus methotrexate, with 46% achieving ACR50 response at 6 months 3
- Monotherapy comparison: Tofacitinib monotherapy (38% ACR50) failed to demonstrate non-inferiority to combination therapy (46% ACR50), indicating the added benefit of methotrexate 3
- Meta-analysis findings: Combination therapy showed significantly better ACR20 (OR 3.62), ACR50 (OR 5.17), and ACR70 (OR 8.44) responses versus methotrexate alone 4
Practical Implementation
Dosing
- Tofacitinib: 5 mg twice daily (standard dose for most countries) 1
- Methotrexate: Continue at established dose when adding tofacitinib
- Dose reduction of tofacitinib required if creatinine clearance <30 mL/min 1
When to Use Combination
Use tofacitinib plus methotrexate when:
- Inadequate response to methotrexate alone after 3-6 months 2
- Poor prognostic factors present (high RF/ACPA, high disease activity, early joint damage) 2
- Patient requires more aggressive disease control
Safety Considerations
The combination is generally well-tolerated, with some important caveats:
- Hepatotoxicity monitoring: Interestingly, combination therapy showed LOWER rates of abnormal liver enzymes compared to methotrexate monotherapy (OR 1.86 favoring combination) 4
- Drug interactions: The FDA label notes methotrexate interactions with various agents, but tofacitinib is not listed as contraindicated 5
- Infection risk: Monitor for serious infections, particularly herpes zoster (higher with tofacitinib) 6
- Cardiovascular risk: Be cautious in patients with cardiovascular risk factors, particularly regarding VTE/PE risk with tofacitinib 10 mg twice daily 1
Common Pitfalls to Avoid
- Don't use tofacitinib 10 mg twice daily routinely - the 5 mg twice daily dose is standard, with 10 mg associated with increased VTE/PE risk 1
- Don't assume monotherapy is equivalent - evidence clearly shows combination therapy is superior 3
- Don't discontinue methotrexate prematurely - patients achieving remission/LDA can maintain response if methotrexate is discontinued, but this should be a deliberate decision after achieving target 7
When Methotrexate Can Be Discontinued
Once patients achieve sustained remission or low disease activity with combination therapy, methotrexate can potentially be discontinued while continuing tofacitinib, with 70.4% maintaining remission/LDA at year 3 7. However, methotrexate may have a protective effect against disease flare upon tofacitinib withdrawal 8.
Bottom line: Combining tofacitinib with methotrexate is not only safe but represents optimal therapy for most patients with active RA who have failed methotrexate monotherapy.